Premier Biomedical Inc (BIEI) financial statements (2021 and earlier)

Company profile

Business Address P.O. BOX 25
JACKSON CENTER, PA 16133
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments117878187631079
Cash and cash equivalents117878187631079
Receivables32232  
Inventory, net of allowances, customer advances and progress billings2122242611912379
Inventory2122242611912379
Other current assets36354044383633
Total current assets:178147148160222170192
Noncurrent Assets
Property, plant and equipment8975667
Total noncurrent assets:8975667
TOTAL ASSETS:186155155165228176199
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities242264294286329361356
Accounts payable193225268264307348347
Interest and dividends payable4939262222149
Debt192250253310304218155
Due to related parties31323026313741
Other undisclosed current liabilities1,8391,7531,5511,6901,8081,5861,574
Total current liabilities:2,3042,2982,1282,3122,4722,2032,126
Noncurrent Liabilities
Total liabilities:2,3042,2982,1282,3122,4722,2032,126
Stockholders' equity
Stockholders' equity attributable to parent, including:(2,118)(2,143)(1,973)(2,147)(2,244)(2,027)(1,927)
Preferred stock   2222
Common stock0000007
Common stock, value, subscriptions  7    
Additional paid in capital14,94714,74114,67814,57313,96813,83313,826
Accumulated deficit(17,068)(16,886)(16,659)(16,728)(16,226)(15,862)(15,762)
Other undisclosed stockholders' equity attributable to parent222513  
Total stockholders' equity:(2,118)(2,143)(1,973)(2,147)(2,244)(2,027)(1,927)
TOTAL LIABILITIES AND EQUITY:186155155165228176199

Income statement (P&L) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Revenues346981210
Cost of revenue(2)(2)(2)(93)(4)(10)(6)
Cost of goods and services sold      (6)
Gross profit:224(84)424
Operating expenses(66)(75)(86)(378)(85)(82)(74)
Operating loss:(65)(73)(82)(462)(81)(80)(70)
Nonoperating income (expense)(117)(154)151(40)(282)(20)636
Interest and debt expense(56)(38)(8)(93)(185)(74)(64)
Net income (loss):(238)(265)61(595)(548)(174)502
Other undisclosed net income attributable to parent56388931857464
Net income (loss) available to common stockholders, diluted:(182)(227)69(502)(364)(100)566

Comprehensive Income ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net income (loss):(238)(265)61(595)(548)(174)502
Comprehensive income (loss), net of tax, attributable to parent:(238)(265)61(595)(548)(174)502

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: